

Ggt1	Gamma-glutamyltransferase 1	2,603 ± 1,372
Other Genes Related to Drug Metabolism		
Arnt	Aryl hydrocarbon receptor nuclear translocator	1,613 ± 0,493
Ahr	Aryl hydrocarbon receptor	1,548 ± 0,401
Asna1	ArsA arsenite transporter, ATP-binding, homolog 1 (bacterial)	0,914 ± 0,065
Gckr	Glucokinase (hexokinase 4) regulator	0,004 ± 0,002*
Mareks	Myristoylated alanine rich protein kinase C substrate	0,753 ± 0,027*
Smarca11	Swi/SNF related matrix associated, actin dependent regulator of chromatin, subfamily a-like 1	1,198 ± 0,126
Snn	Stannin	0,637 ± 0,025*
Carboxylesterases		
Ces1e	Carboxylesterase 1E	2,695 ± 1,571
Ces2c	Carboxylesterase 2C	0,986 ± 0,007*
Decarboxylases		
Gad1	Glutamic acid decarboxylase 1	0,946 ± 0,005*
Gad2	Glutamic acid decarboxylase 2	0,387 ± 0,034*
Dehydrogenases		
Adh1	Alcohol dehydrogenase 1 (class I)	3,011 ± 1,568
Adh4	Alcohol dehydrogenase 4 (class II), pi polypeptide	3,272 ± 1,923
Alad	Aminolevulinate, delta-, dehydratase	0,500 ± 0,396
Aldh1a1	Aldehyde dehydrogenase 1 family, member A1	1,765 ± 0,582
Hsd17b1	Hydroxysteroid (17-beta) dehydrogenase 1	2,099 ± 1,115
Hsd17b2	Hydroxysteroid (17-beta) dehydrogenase 2	3,011 ± 1,679
Hsd17b3	Hydroxysteroid (17-beta) dehydrogenase 3	2,297 ± 1,107
Glutathione Peroxidases		
Gpx1	Glutathione peroxidase 1	1,110 ± 0,085
Gpx2	Glutathione peroxidase 2	2,071 ± 0,899
Gpx3	Glutathione peroxidase 3	1,580 ± 0,414
Gpx4	Glutathione peroxidase 4	0,012 ± 0,003*
Gpx5	Glutathione peroxidase 5	1,043 ± 0,021
Lpo	Lactoperoxidase	2,042 ± 0,902
Mpo	Myeloperoxidase	2,549 ± 1,318
Hydrolases		
Ephx1	Epoxide hydrolase 1, microsomal	0,732 ± 0,266
Faah	Fatty acid amide hydrolase	0,796 ± 0,019*
Fbp1	Fructose-1,6-bisphosphatase 1	2,514 ± 1,297
Kinases		
Hk2	Hexokinase 2	0,012 ± 0,005*
Pklr	Pyruvate kinase, liver and RBC	0,865 ± 0,154
Pkm2	Pyruvate kinase, muscle	0,859 ± 0,031*




Figure 1. Effects of KA treatment on mRNA expression levels of drug transporters, P-glycoprotein family, and Phase I metabolizing enzymes in hippocampus. Data were expressed as mean \pm standard error. $*p < 0.05$ vs control in hippocampus (n=6 for each group).




Figure 2. Effects of KA treatment on mRNA expression levels of Phase II metabolizing enzymes in hippocampus. Data were expressed as mean \pm standard error. $*p < 0.05$ vs control in hippocampus (n=6 for each group).